有机阴离子转运多肽1B1(OATP1B1)遗传多态性对瑞格列奈药动学的影响

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (9): 990-994.

有机阴离子转运多肽1B1(OATP1B1)遗传多态性对瑞格列奈药动学的影响

阳国平¹, 宋敏², 谭鸿毅¹, 刘纯¹, 黄志军¹, 刘畅¹, 阳丽¹, 向红¹, 付志敏², 黄原原²

¹中南大学湘雅三医院,²中南大学药学院, 长沙410013, 湖南

收稿日期:2009-08-31 修回日期:2009-09-23 发布日期:2020-11-03
通讯作者: 刘纯, 女, 硕士, 主治医师, 主要研究方向:慢性阻塞性肺疾病营养不良相关研究。Tel:0731-88618116 E-mail: liuchun7322@sohu.com
作者简介:阳国平, 男, 副教授, 硕士生导师, 主要研究方向:临床药理学和药物研发。Tel:0731-88618339 E-mail: ygp9880@163. com

Effects of genetic polymorphism of OATP1B1 on pharmacokinetics of repaglinide

YANG Guo-ping¹, SONG Min², TAN Hong-yi¹, LIU Chun¹, HUANG Zhi-jun¹, LIU Chang¹, YANG Li¹, XIANG Hong¹, FU Zhi-min², HUANG Yuan-yuan²

¹Xiangya 3rd Hospital of Central-South University, ²School of Pharmaceutical Sciences of Central-South University, Changsha 410013, Hunan, China

Received:2009-08-31 Revised:2009-09-23 Published:2020-11-03

摘要/Abstract

摘要： 目的: 研究有机阴离子转运多肽1B1(OATP1B1) 遗传多态性对瑞格列奈药动学的影响。方法: 16 名健康男性受试者单剂量po 4 mg瑞格列奈片, 并考察其SLCO1B1 (OATP1B1 的编码基因) 常见单体型(SLCO1B1^*1a 、^*1b 、^*5 和^*15), 按基因型将其分成^*1b/^*1b 、^*1a/^*1a 或^*1a/^*1b 、^*1a/^*15 或^*1b/^*15 三组, 采用HPLC-MSMS法测定给药后不同时间瑞格列奈的血药浓度。利用DAS 2.0 计算药动学参数和SPSS 12.0 评价统计学差异。结果: SLCO1B1^*1b/^*1b 、SLCO1B1^*1a/^*1a 或^*1a/^*1b 和SLCO1B1^*1a/^*15 或^*1b/^*15 三组受试者的AUC_{0-8 h} 分别为(63±20) 、(70±26) 和(82±24) μg·L^-1 ·h, C_max 分别为(56±16) 、(52±17) 和(58±34) μg/L, 三者之间差异没有统计学意义。结论: OATP1B1 遗传多态性对瑞格列奈药动学有影响, 但从本试验结果看, 三组之间的差异较小, 还不足以影响临床用药的安全性和有效性。

关键词: 瑞格列奈, 有机阴离子转运多肽1B1, 遗传多态性, 药动学

Abstract: AIM: To investigate the effects of the genetic polymorphism of organic anion transporting polypeptide 1B1 (OATP1B1) on the pharmacokinetic profile of repaginide in Chinese subjects. METHODS: The common haplotypes of SLCO1B1 (the coding gene of OATP1B1), which were reported as SLCO1B1 ^* 1a, ^* 1b, ^* 5 and ^* 15, were determined in 16 healthy male volunteers with the genotypes of ^* 1b/^* 1b, ^* 1a/^* 1a or ^* 1a/^* 1b, ^* 1a/^* 15 or ^* 1b/^* 15.A single dose (4 mg) of repaglinide tablets was given orally. The plasma concentrations of repaglinide were determined by HPLC-MS-MS method. The pharmacokinetic parameters were obtained by DAS Ver 2.0.The statistical differences of the pharmacokinetic parameters were assessed by SPSS 12.0.RESULTS: The values of AUC_{0-8 h} of SLCO1B1 ^* 1b/^* 1b, SLCO1B1 ^* 1a/^* 1a or ^* 1a/^* 1b and SLCO1B1 ^* 1a/^* 15 or ^* 1b/^* 15 three groups were (63±20), (70±26) and (82±24) μg·L^-1 ·h respectively. The values of C_max were (56± 16), (52±17) and (58±34) μg/L respectively. There were no significant differences between any two groups. CONCLUSION: The pharmacokinetic profile of repaglinide was affected by the genetic polymorphism of OATP1B1, but the difference from this experiment is not large enough to affect clinical drug safety and effectiveness.

Key words: repaglinide, organic anion transporting polypeptide 1B1, genetic polymorphism, pharmacokinetics

中图分类号:

R969

阳国平, 宋敏, 谭鸿毅, 刘纯, 黄志军, 刘畅, 阳丽, 向红, 付志敏, 黄原原. 有机阴离子转运多肽1B1(OATP1B1)遗传多态性对瑞格列奈药动学的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 990-994.

YANG Guo-ping, SONG Min, TAN Hong-yi, LIU Chun, HUANG Zhi-jun, LIU Chang, YANG Li, XIANG Hong, FU Zhi-min, HUANG Yuan-yuan. Effects of genetic polymorphism of OATP1B1 on pharmacokinetics of repaglinide[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 990-994.

参考文献

[1] Hagenbuch B, Meier PJ.Organic anion transporting polypeptides of the OATP SLC21 family: phylogenetic classification as OATP SLCO superfamily, new nomenclature and molecular functional properties[J]. Pflugers Arch, 2004, 447(5): 653-665.
[2] Niemi M.Role of OATP transporters in the disposition of drugs[J]. Pharmacogenomics, 2007, 8(7): 787-802.
[3] Nozawa T, Nakajima M, Tamai I, et al.Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B(SLC21A9): allele frequencies in the Japanese population and functional analysis[J]. J Pharm Acol Exp Ther, 2002, 302(2): 804-813.
[4] Niemi M, Schaeffeler E, Lang T, et al.High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)[J]. Pharmacogenetics, 2004, 14(7): 429-440.
[5] Reinhold K.Implications of genetic polymorphisms in drug transporters for pharmacotherapy[J]. Cancer Lett, 2006, 234(1): 4-33.
[6] Kim EY, Cho DY, Shin HJ, et al.Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations[J]. Clin Chim Acta, 2008, 388(1 2): 68-72.
[7] Niemi M, Backman JT, Kajosaari LI, et al.Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics[J]. Clin Pharmacol Ther, 2005, 77(6): 468-78.
[8] Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1* 5, SLCO1B1* 15 and SLCO1B1* 15 + C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005, 15(7): 513-522.
[9] Maeda K, Ieiri I, Yasuda K, et al.Effects of organic anion transporting polypeptide 1B1 haplotype on pharmaco-kinetics of pravastatin, valsartan, and temocapril[J]. Clin Pharmacol Ther, 2006, 79(5): 427-439.
[10] Kalliokoski A, Backman JT, Neuvonen PJ, et al.Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. Pharmacogenet Genomics, 2008, 18(11): 937-942.
[11] Deng JW, Song IS, Shin HJ, et al.The effect of SLCO1B1 *15 on the disposition of pravastatin and pitavastatin is substrate dependent:the contribution of transporting activity changes by SLCO1B1 * 15[J]. Pharmacogenet Genomics, 2008, 18(5): 424-433.
[12] Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. J Clin Pharmacol, 2008, 48(3): 311-321.
[13] Kalliokoski A, Backman JT, Kurkinen KJ, et al.Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism[J]. Clin Pharmacol Ther, 2008, 84(4): 488-496.
[14] S.Schmacher I, Abbasi D,Weise V, et al. Single-and multiple- dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment[J]. Eur J Clin Pharmacol, 2001, 57(2): 147-152.
[15] Ruzilawati AB, Wahab MS, Imran A, et al.Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies[J]. J Pharm Biomed Anal, 2007, 43(5): 1831-1835.
[16] Kalliokoski A, Backman JT, Kurkinen KJ, et al.Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism[J]. Clin Pharmacol Ther, 2008, 84(4): 488-496.
[17] Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide[J]. Br J Clin Pharmacol, 2006, 62(5): 567-572.
[18] Nishizato Y, Ieiri I, Suzuki H, et al.Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:consequences for pravastatin pharmacokinetics[J]. Clin Pharmacol Ther, 2003, 73(6): 554-565.
[19] Mwinyi J, Johne A, Bauer S, et al.Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics[J]. Clin Pharmacol Ther, 2004, 75(5): 415-421.
[20] Ho RH, Choi L, Lee W, et al.Effect of drug transporter genotypes on pravastatin disposition in European-and African- American participants[J]. Pharmacogenet Genomics, 2007, 17(8): 647-656.
[21] Choi JH, Lee MG, Cho JY, et al.Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans[J]. Clin Pharmacol Ther, 2008, 83(2): 251-257.